ONWARD Medical Launches Pivotal Study for Spinal Cord Injury Blood Pressure Therapy

Event summary

  • ONWARD Medical has enrolled the first participant in its global Empower BP study evaluating the ARC-IM System for blood pressure instability in spinal cord injury (SCI) patients.
  • The randomized, double-blinded, sham-controlled study will involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada, France, Germany, Spain, and the UK.
  • The ARC-IM System aims to address chronic orthostatic hypotension and autonomic dysreflexia, conditions affecting 78% of tetraplegia patients but treated in only 28% of cases.
  • Previous clinical feasibility studies published in Nature Medicine showed immediate and robust increases in blood pressure, reduced hypotensive symptoms, and improved quality of life for participants.

The big picture

ONWARD Medical's Empower BP study represents a significant step in addressing a critical unmet need in spinal cord injury care. Blood pressure instability is a debilitating condition for many SCI patients, with limited treatment options currently available. The study's success could position ONWARD Medical as a leader in neurotechnology solutions for autonomic dysfunction, potentially expanding its market beyond movement restoration to include broader autonomic function management.

What we're watching

Clinical Success
Whether the ARC-IM System can replicate its feasibility study results in the larger, pivotal Empower BP trial, which will be critical for regulatory approval and commercialization.
Market Expansion
The pace at which ONWARD Medical can expand the study to additional centers and enroll more participants, which will determine the timeline for potential FDA approval and market entry.
Competitive Positioning
How ONWARD Medical's ARC-IM System differentiates itself from existing treatments for blood pressure instability in SCI patients, particularly given the high unmet need in this area.

Related topics

Biotechnology